logo
BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Yahoo06-05-2025
BioCryst Pharmaceuticals (BCRX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
The earnings report, which is expected to be released on May 5, 2025, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus Estimate
This drugmaker is expected to post quarterly loss of $0.07 per share in its upcoming report, which represents a year-over-year change of +58.8%.
Revenues are expected to be $126.59 million, up 36.5% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 3.13% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Earnings Whisper
Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why Oscar Health, Inc. (OSCR) Outpaced the Stock Market Today
Why Oscar Health, Inc. (OSCR) Outpaced the Stock Market Today

Yahoo

time2 days ago

  • Yahoo

Why Oscar Health, Inc. (OSCR) Outpaced the Stock Market Today

In the latest trading session, Oscar Health, Inc. (OSCR) closed at $14.45, marking a +1.76% move from the previous day. This change outpaced the S&P 500's 0.4% gain on the day. Meanwhile, the Dow gained 0.47%, and the Nasdaq, a tech-heavy index, added 0.24%. The company's stock has dropped by 30.66% in the past month, falling short of the Finance sector's gain of 3.3% and the S&P 500's gain of 4.61%. The upcoming earnings release of Oscar Health, Inc. will be of great interest to investors. The company's earnings report is expected on August 6, 2025. The company is expected to report EPS of -$0.59, down 395% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $2.89 billion, up 30.15% from the year-ago period. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.68 per share and revenue of $11.87 billion. These totals would mark changes of -780% and +29.34%, respectively, from last year. Investors might also notice recent changes to analyst estimates for Oscar Health, Inc. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 211.41% downward. Right now, Oscar Health, Inc. possesses a Zacks Rank of #4 (Sell). The Insurance - Multi line industry is part of the Finance sector. This group has a Zacks Industry Rank of 159, putting it in the bottom 36% of all 250+ industries. The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Keep in mind to rely on to watch all these stock-impacting metrics, and more, in the succeeding trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Oscar Health, Inc. (OSCR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤

Jefferies (JEF) Up 1.7% Since Last Earnings Report: Can It Continue?
Jefferies (JEF) Up 1.7% Since Last Earnings Report: Can It Continue?

Yahoo

time2 days ago

  • Yahoo

Jefferies (JEF) Up 1.7% Since Last Earnings Report: Can It Continue?

A month has gone by since the last earnings report for Jefferies (JEF). Shares have added about 1.7% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Jefferies due for a pullback? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent drivers for Jefferies Financial Group Inc. before we dive into how investors and analysts have reacted as of late. Jefferies Q2 Earnings Meet Estimates on Solid Equity Trading Jefferies' second-quarter fiscal 2025 (ended May 31) adjusted earnings of 43 cents per share matched the Zacks Consensus Estimate. The bottom line compared unfavorably with the prior-year quarter's earnings of 67 cents per were aided by strong equity trading performance. However, weak performances in the IB and asset management businesses, alongside higher expenses, remain a spoilsport. Net income attributable to common shareholders (GAAP basis) was $88 million, declining from $145.7 million in the prior-year quarter. Jefferies' Revenues Decline, Expenses Rise Quarterly net revenues were $1.63 billion, down 1.3% year over year. The top line surpassed the Zacks Consensus Estimate of $1.56 non-interest expenses were $1.50 billion, up 5% from the prior-year quarter. The rise was due to an increase in almost all cost components except compensation and benefits and underwriting of May 31, 2025, book value per common share was $49.96, up from $46.57 as of May 31, 2024. Further, adjusted tangible book value per fully diluted share of $32.84 increased from $31.27. Jefferies's Quarterly Segment Performance Investment Banking and Capital Markets: Net revenues were $1.47 billion, falling 1.6% from the prior-year quarter. The decline was due to subdued equity & debt underwriting and fixed-income trading performance in capital markets, partially offset by a robust performance in equities trading Management: Net revenues were $154.6 million, down 1.2% from the year-ago quarter. How Have Estimates Been Moving Since Then? In the past month, investors have witnessed a flat trend in estimates review. The consensus estimate has shifted -11.36% due to these changes. VGM Scores At this time, Jefferies has a poor Growth Score of F, a score with the same score on the momentum front. Charting a somewhat similar path, the stock has a grade of D on the value side, putting it in the bottom 40% for this investment strategy. Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in. Outlook Jefferies has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Jefferies Financial Group Inc. (JEF) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio

Sallie Mae Q2 Earnings Miss Estimates, Expenses & Provisions Rise Y/Y
Sallie Mae Q2 Earnings Miss Estimates, Expenses & Provisions Rise Y/Y

Yahoo

time2 days ago

  • Yahoo

Sallie Mae Q2 Earnings Miss Estimates, Expenses & Provisions Rise Y/Y

Sallie Mae SLM reported second-quarter 2025 earnings per share (EPS) of 32 cents, which missed the Zacks Consensus Estimate of 49 cents. The bottom line declined from the prior-year quarter's EPS of $1.11. The quarterly results were affected by higher provisions for credit losses, a fall in non-interest income and a rise in expenses. Nonetheless, a rise in net interest income (NII) was positive. The company's GAAP net income was $71 million compared with $252 million in the prior-year quarter. Sallie Mae's NII & Expenses Rise Second-quarter NII totaled $376.8 million, up 1.2% year over year. The reported figure beat the Zacks Consensus Estimate by 0.5%. The quarterly net interest margin was 5.31%, which shrank 5 basis points from the prior-year quarter. Non-interest income amounted to $26.8 million, down from $141.8 million in the year-ago quarter. Non-interest expenses rose 5.5% year over year to $167.2 million. SLM's Credit Quality Deteriorates Provision for credit losses was $148.7 million, up from $16.8 million in the prior-year quarter. Net charge-offs for private education loans were $94 million, up 17.5% year over year. Private education loans held for investment net charge-offs, as a percentage of average private education loans held for investment in repayment (annualized), were 2.36%. The figure expanded 17 basis points year over year. Sallie Mae's Balance Sheet Position Improves As of June 30, 2025, deposits were $20.5 billion, up 2% sequentially. Private education loans held for investment were $21.2 billion, up 14.8% from the prior-year quarter. In the reported quarter, the company's private education loan originations declined marginally from the year-ago quarter to $686 million. SLM's Share Repurchase Update In the second quarter, SLM repurchased 2.4 million shares for $70 million under its 2024 share buyback program. Sallie Mae's 2025 Outlook Reaffirmed The company expects diluted earnings per share of $3.00-$3.10. SLM anticipates total loan portfolio net charge-offs as a percentage of average loans in repayment of 2-2.2%. Private education loan originations are expected to grow 6-8% year over year. SLM's non-interest expenses are expected to be $655-$675 million. Final Thoughts on SLM Sallie Mae's overall financial performance seems decent. Robust loan origination and a rise in net interest income are encouraging. However, a rise in provisions for credit losses is a major near-term headwind. SLM Corporation Price, Consensus and EPS Surprise SLM Corporation price-consensus-eps-surprise-chart | SLM Corporation Quote Currently, SLM carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Performances of Other Banks Hancock Whitney Corp.'s HWC second-quarter 2025 adjusted earnings per share of $1.37 exceeded the Zacks Consensus Estimate of $1.34. The bottom line rose 4.6% from the prior-year quarter. HWC's results benefited from an increase in non-interest income and NII. Also, higher loans were another positive. However, higher adjusted expenses and provisions alongside lower deposit balances were headwinds. Bank OZK's OZK second-quarter 2025 earnings per share of $1.58 surpassed the Zacks Consensus Estimate of $1.51. Moreover, the bottom line reflected a rise of 3.9% from the prior-year quarter's actual. Overall, OZK's results benefited from a rise in NII and non-interest income, and lower provisions. Also, higher loans and deposit balances were other positives. However, higher non-interest expenses acted as spoilsports. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report SLM Corporation (SLM) : Free Stock Analysis Report Hancock Whitney Corporation (HWC) : Free Stock Analysis Report Bank OZK (OZK) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store